A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model
PLOS ONE · 08.08.2024 · 19 (8) · e0308671
DOI: 10.1371/journal.pone.0308671 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 08.08.2024. Verfasst von Ruta Maciulaitiene und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Academy of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania. Hauptthemen laut MEDLINE: Glaucoma, Brimonidine Tartrate, Neuroprotective Agents, Retinal Ganglion Cells. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glaucoma is a multifactorial optic neuropathy that primarily affecting retinal ganglion cells (RGC). Brimonidine is an intraocular pressure-lowering drug with reported neuroprotective properties. This study aimed to compare the neuroprotective effects of topical and intraperitoneal (IP) brimonidine on RGCs from different retinal segments in a murine optic nerve crush (ONC) model. Methods: forty-one Balb/c mice underwent unilateral ONC and were divided into three study groups: fifteen animals received saline drops twice per day and two additional IP injections of saline; fourteen mice received brimonidine drops twice per day; and 12 mice received brimonidine eye drops twice per day and two additional IP brimonidine injections. Animals were sacrificed seven days post-ONC, and immunohistochemical staining of retinal whole mounts was performed using neuronal NeuN and GFAP staining. Microscopic pictures of the central, middle, and peripheral regions of the retina were taken. The density of the retinal cells was assessed. Results: The total RGC density after ONC and RGC densities in all retinal eccentricities were significantly higher in the brimonidine eye drop and IP combination treatment group than in the saline drop + saline IP, and brimonidine drop treatment groups. Conclusions: brimonidine eye drops supplemented with IP brimonidine injections improved RGC survival in a preclinical model of ONC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Academy of Medicine, Lithuanian University of Health Sciences, Kaunas, Lithuania.
- Experimentica Ltd., Kuopio, Finland.
- Experimentica UAB, Vilnius, Lithuania.
- Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Academy of Medicine, Institute of Anatomy, Lithuanian University of Health Sciences, Kaunas, Lithuania.
ORCID-Profile: Ruta Maciulaitiene, Ingrida Januleviciene
Zitieren
APA
Maciulaitiene, R., Kalesnykas, G., Pauza, D. H., & Januleviciene, I. (2024). A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model. PLOS ONE, 19(8), e0308671. https://doi.org/10.1371/journal.pone.0308671
Vancouver
Maciulaitiene R, Kalesnykas G, Pauza DH, Januleviciene I. A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model. PLOS ONE. 2024;19(8):e0308671. doi:10.1371/journal.pone.0308671
BibTeX
@article{Maciulaitiene2024,
author = {Maciulaitiene, Ruta and Kalesnykas, Giedrius and Pauza, Dainius Haroldas and Januleviciene, Ingrida},
title = {A combination of topical and systemic administration of brimonidine is neuroprotective in the murine optic nerve crush model},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {8},
pages = {e0308671},
doi = {10.1371/journal.pone.0308671}
}
EUVIMED